{'fraction_non_alphanumeric': 0.04285714285714286, 'fraction_numerical': 0.033928571428571426, 'mean_word_length': 5.303370786516854, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
High expression of NFX1‐123 in HPV positive head and neck squamous cell carcinomas

High‐risk human papillomaviruses (HR HPV) cause nearly all cervical cancers and, in the United States, the majority of head and neck cancers (HNSCCs). NFX1‐123 is overexpressed in cervical cancers, and NFX1‐123 partners with the HR HPV type 16 E6 oncoprotein to affect multiple growth, differentiation, and immune response genes. However, neither the expression of NFX1‐123 nor the levels of these genes have been investigated in HPV positive (HPV+) or negative (HPV−) HNSCCs.